India’s IPCA says Global Fund stops buying its anti-malarial drugs

India’s IPCA Laboratories Ltd said on Thursday that the Global Fund to Fight AIDS, Tuberculosis and Malaria, would no longer buy the company’s anti-malarial treatments after a U.S. regulatory warning about quality lapses at its factories. IPCA said in February that the U.S. Food and Drug Administration had issued it with a warning letter outlining manufacturing quality lapses observed at three of its Indian factories. The Global Fund will no longer source Artemisinin-based Combination Therapy (ACTs), an anti-malarial treatment, from IPCA following a “risk consideration exercise”, the drugmaker said.
Go to Source